Intestinal transformation results in transforming growth factor-beta-dependent alteration in tumor cell-cell matrix interactions

Surgery

Volumn 133, Issue 5, 2003, Pages 568-579

  Berger, David H ^a   O'Mahony, Christine A ^b   Sheng, Hongmiao ^b   Shao, Jinyi ^b   Albo, Daniel ^b   DuBois, Raymond N ^b   Beauchamp, R Daniel ^b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; COLLAGEN TYPE 1; COLLAGEN TYPE 4; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FIBRONECTIN; LAMININ; TRANSFORMING GROWTH FACTOR BETA; UROKINASE;

ANIMAL CELL; ARTICLE; CANCER INVASION; CARCINOGENESIS; CELL ADHESION; CELL INTERACTION; COLORECTAL CARCINOMA; CONCENTRATION RESPONSE; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; IN VITRO STUDY; INTESTINE EPITHELIUM CELL; MALIGNANT TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

EID: 0038779478     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1067/msy.2003.125     Document Type: Article

References (57)

1. Barnard JA Beauchamp RD Coffey RJ Moses HL Regulation of intestinal epithelial cell growth by transforming growth factor type beta Proc Natl Acad Sci USA 1989;86:1578-89
2. Sheng H, Shao J, O'Mahony CA, Lamps L, Albo D, Isakson PC, et al. Transformation of intestinal epithelial cells by chronic TGF-beta 1 treatment results in downregulation of the type II TGF-beta receptor and induction of cyclooxygenase-2. Oncogene 1999;18:855-67.
3. Avery A, Paraskeva C, Hall P, Flanders KC, Sporn M, Moorghen M. TGF-beta expression in the human colon: differential immunostaining along the crypt epithelium. Br J Cancer 1993;68:137-9.
4. Manning AM, Williams AC, Game SM, Paraskeva C. Differential sensitivity of human colonic adenoma and carcinoma cells to transforming growth factor beta (TGF-beta): conversion of an adenoma cell line to a tumorigenic phenotype is accompanied by a reduced response to the inhibitory effects of TGF-beta. Oncogene 8:1991;1471-6.
5. Laiho M, Oaksela O, Keski-Oja J. Transforming growth factor-beta induction of type-1 plasminogen activator inhibitor: pericellular distribution and sensitivity to exogenous urokinase. J Biol Chem 269:1987;17467-74.
6. Laiho M, Saksela O, Andreasen PA, Keski-Oja J. Enhanced production and extracellular deposition of the endothelial-type plasminogen activator inhibitor in cultured human lung fibroblasts by transforming growth factor-beta. J C Biol 1986;103:2403-10.
7. Johnsen M, Lund LR, Romer J, Almholt K, Dano K. Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr Opin Cell Biol 1998;10:667-71.
8. Albo D, Berger DH, Wang TN, Hu X, Rothman V, Tuszynski GP. Thrombospondin-1 and transforming growth factor-beta 1 promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin system. Surgery 1997;122:493-9.
9. Albo D, Berger DH, Tuszynski GP. The effect of thrombospondin-1 and TGF-beta1 on pancreatic cancer cell invasion. J Surg Res 1998;76:86-90.
10. Arnoletti JP, Albo D, Granick MS, Solomon MP, Castiglioni A, Rothman VL, Tuszynski GP. Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB321 breast cancer cells. Cancer 1995;76:998-1005.
11. Farina AR, Coppa A, Tiberio A, Iacconnelli A, Turco A, Colletta G, et al. Transforming growth factor-beta 1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity. Int J Cancer 1998;75:721-30.
12. Lund LR, Romer J, Ronne E, Ellis V, Blasi F, Dano K. Urokinase-receptor biosynthesis mRNA level and gene transcription are increased by transforming growth factor beta1 in human A549 lung carcinoma cells. EMBO J 1991;10:3399-3407.
13. Sehgal I, Baley PA, Thompson TC. Transforming growth factor-beta 1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro. Cancer Res 1996;56:3359-65.
14. Albo D, Arnoletti JP, Castiglion IA, Granick MS, Solomon MP, Rothman VL, et al. Thrombospondin (TSP) and transforming growth factor beta 1 (TGF-beta) promote human A549 lung carcinoma cell plasminogen activator inhibitor type 1 production and stimulate tumor cell attachment in vitro. Biochem Biophys Res Commun 1994;203:857-65.
15. Sheng H, Shao J, Hooton EB, Tsujii M, DuBois RN, Beauchamp RD. Cyclooxygenase-2 induction and transforming growth factor beta growth inhibition in rat intestinal epithelial cells. Cell Growth Diff 1997;8:463-70.
16. Jackson BA, Goldstein RH, Roy R, Cozzani M, Taylor L, Polgat P. Effects of transforming growth factor beta and interleukin-1beta on expression of cyclooxygenase 1 and 2 and phospholipase A mRNA in lung fibroblasts and endothelial cells in culture. Biochem Biophys Res Commun 1993;197:1465-74.
17. Diaz A, Chepenik KP, Korn JH, Reginato AM, Jimenez SA. Differential regulation of cyclooxygenases 1 and 2 by interleukin-1beta tumor necrosis factor-alpha and transforming growth factor-beta1 in human lung fibroblasts. Exp Cell Res 1998;241:222-9.
18. Vane RJ. Towards a better aspirin. Nature 1994;367:215-6.
19. O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993;330:156-60.
20. Maier JAM, Hla T, Maciag H. Cyclooxygenase is an immediate-early gene induced by interleukin-1 in human endothelial cells. J Biol Chem 1990;265:10805-8.
21. Levy GN. Prostaglandin H synthases nonsteroidal anti-inflammatory drugs and colon cancer. FASEB J 11:234-47.
22. Lee SH, Soyoola E, Chanmugam P, Hart S, Sun W, Zhong H. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide J Biol Chem 1992;267:25934-8.
23. Minghetti L, Polazzi E, Nicolini A, Levi G. Opposite regulation of prostaglandin E2 synthesis by transforming growth factor-beta1 and interleukin 10 in activated microglial cultures. J Neuroimmunol 1998;82:31-9.
24. Tsushima H, Kawata S, Tamura S, Ito N, Shirai Y, Kiso S, et al. High levels of transforming growth factor beta 1 in patients with colorectal cancer: association with disease progression. Gastroenterology 1996;110:375-82.
25. Sun L, Wu G, Wilson JK, Zborowska EJ, Yang I, Rajkarunanayake J, et al. Expression of transforming growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J Biol Chem 1994;269:26449-55.
26. Grady WM, Rajput A, Myeroff L, Kwon KH, Willis J, Markowitz S. Mutation of the type II transforming growth factor-B receptor is coincident with the transformation of human colon adenomas to malignant carcinomas Cancer Res 1998;58:3101-4.
27. Friedman E, Gold LI, Klemstra D, Zeng ZS, Winaver S, Cohen A. High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomarkers Prev 1995;4:549-54.
28. Newman MJ. Transforming growth factor beta and the cell surface in tumor progression. Cancer Metastasis Rev 1993;12:239-54.
29. Hoosein NM, McKnight MK, Levine AE, Mulder KM, Childress KE, Brattain DE, et al. Differential sensitivity of sub-classes of human colon carcinoma cell lines to the growth inhibitory effects of transforming growth factor-beta 1. Exp Cell Res 1989;181:442-53.
30. Shim KS, Kim KH, Han WS, Park EB. Elevated serum levels of transforming growth factor-b1 in patients with colorectal carcinoma. Cancer 1999;85:554-61.
31. Heldin CH, Miyazono K, Dijke P. TGF-beta signaling from cell membrane to nucleus through SMAD proteins. Nature 1997;390:465-71.
32. Zhu Y, Richardson JA, Parada LF, Graff JM. Smad 3 mutant mice develop metastatic colorectal cancer. Cell 1998;94:703-14.
33. Bresalier RS. Tumor progression in the intestine: smad about you. Gastroenterology 1998;115:1598-9.
34. Wang J, Sun LZ, Myeroff L, Wang X, Gentry LE, Yang J, et al. Demonstration that mutation of the type II transforming growth factor beta receptor inactivates its tumor suppressor activity in replication error positive colon carcinoma cells. J Biol Chem 1995;270:22044-9.
35. Zhang T, Nanney LB, Peeler MO, Williams CS, Lamps L, Heppner KL, et al. Decreased transforming growth factor beta type II receptor expression in intestinal adenomas from Min/+ mice is associated with increased cyclin D1 and cyclin-dependent kinase 4 expression. Cancer Res 1997;57:1638-43.
36. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995;268:1336-8.
37. MacKay SLD, Yaswen LR, Tarnuzzer RW, Moldawer LL, Bland KL, Copeland EM, et al. Colon cancer cells that are not growth inhibited by TGF-beta lack functional type I and type II receptors. Ann Surg 1995;221:767-7.
38. Park J, Kim SJ, Bang Y. Genetic changes in the transforming growth factor type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta. Proc Nat Acad Sci U S A 1994;91 8772-6.
39. Takagi Y, Koumura H, Futamura M, Aoki S, Ymaguchi K, Kida H, et al. Somatic alterations of the Smad-2 gene in human colorectal cancers. Br J Cancer 1998;78:1152-5.
40. Miyaki M, Iijima T, Konishi M, Sakai K, Ishii A, Yasuno M, et al. Higher frequency of Smad 4 gene mutation in human colorectal cancer with distant metastasis. Oncogene 1999;20:3098-103.
41. Zhang X, Wang T, Batist G, Tsao MS. Transforming growth factor beta 1 promotes spontaneous transformation of cultured rat epithelial cells. Cancer Res 1994;54:6122-8.
42. Cui W, Fowlis DJ, Bryson S, Duffie E, Ireland H, Balmain A, et al. TGFBeta 1 inhibits the formation of benign skin tumors but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 1996;86:531-42.
43. Oft M, Peli J, Rudaz C, Schwartz HD, Beug H, Reichmann E. TGF-beta1 and H-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev 1996;5:2462-77.
44. Grande JP. Role of transforming growth factor-beta in tissue injury and repair. Proc Soc Exp Biol Med 1997;214:27-40.
45. Ossowski L, Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 1983;35:611-9.
46. Kook YH, Adamski J, Zelent A, Ossowski L. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J 1994;13:3983-91.
47. Knoop A, Andreasen PA, Andersen JA, Hansen S, Laenkholm AV, Simonsen AC, et al. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer 1998;77:932-40.
48. Foekens JA, Schmitt M, van Putten WL, Peters HA, Bontenbal M, Janicke F, et al. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 19992;52:6101-5.
49. Foekens JA, Schmitt M, van Putten WL, Peters HA, Kramer MD, Janicke F, et al. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 1994;12:1648-58.
50. Miyake H, Hara I, Yamanaka K, Arakawa S, Kamidono S. Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer. Int J Oncol 1999;14:535-41.
51. Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sorensen S, Dano K, et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship with prognosis. J Nat Cancer Inst 1999;91:869-74.
52. Skelly MM, Troy A, Duffy MJ, Mulcahy HE, Duggan C, Connell TG, O'Donoghue DP, et al. Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome. Clin Cancer Res 1997;3:1837-40.
53. Ganesh S, Sier CF, Heerding MM, van Krieken JH, Griffioen G, Welvaart K, et al. Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer. Br J Cancer 1997;75:1793-1801.
54. Heino J. Biology of tumor cell invasion: interplay of cell adhesion and matrix degradation. Int J Cancer 1996;65:717-22.
55. Stahl A, Mueller BM. Melanoma cell migration on vitronectin: regulation by the components of the plasminogen activation system. Int J Cancer 1997;71:116-22.
56. Chapman HA. Plasminogen activators integrins and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 1997;9:714-24.
57. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci 1997;94:3336-40.